Tag Archives: Epigenomics

August 2016—LabCorp will acquire Sequenom; New York ends state PT services; St. Jude lands CAP ISO 15189 accreditation; Epigenomics’ DNA test included in CRC guideline; OSU to deploy Inspirata digital pathology solution; Mindray’s clinical chemistry analyzer cleared; Successful Keytruda trial stopped early; Top court clarifies autopsy’s place in Texas law; EUA for Siemens Zika assay

January 2014—Epigenomics announced the results from a clinical study that showed methylated SHOX2 to be a sensitive and specific biomarker for therapy monitoring and early detection of tumor response in lung cancer patients.

Epigenomics has submitted to the FDA the fourth and final module of its premarket approval for its blood-based Epi proColon test for the detection of colorectal cancer.